China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP
The National Health Commission of China (NHC) released the Statistical Bulletin on Health Development in...
Fineline Cube
Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...
Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis
Roivant (NASDAQ: ROIV) announced that the US Food and Drug Administration (FDA) has approved Lisraya...
Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026,...
HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
China‑based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026,...
CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD‑1/IL‑15 bispecific fusion protein, has...
Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June...
Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Huadong Medicine (SHE: 000963) announced that its investigational drug HDM2005 has been granted Fast Track...
Micot’s First‑in‑Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of...
NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change
The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales...
China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)
The National Healthcare Security Administration (NHSA) issued the Guiding Opinions on Improving the Payment Management...
Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced its unaudited interim results for...
Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer
Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a...
Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i
Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED...
FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) for the...
NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand...
FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
Johnson & Johnson (J&J, NYSE: JNJ) announced that the US FDA has approved the second...
FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that the US FDA has...
MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health,...
WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June...